Our Technology
Speckleplethysmography (SPG) and photoplethysmography (PPG) are both optical techniques used to measure physiological parameters like tissue oxygenation, but they differ in their underlying principles and practical advantages. SPG, which leverages laser speckle contrast imaging, offers some distinct benefits over PPG, especially in specific contexts for assessing tissue oxygenation. Here’s a breakdown of those advantages based on how they work and their real-world implications:
SPG uses coherent laser light to detect blood flow dynamics through the speckle patterns created by light scattering off moving red blood cells. This makes it particularly sensitive to microcirculatory changes, which are critical for understanding tissue oxygenation at a deeper and more detailed level. PPG, on the other hand, relies on the absorption of light (typically from LEDs) by hemoglobin to measure blood volume changes, primarily in larger vessels like arteries. While PPG is excellent for tracking arterial oxygen saturation (SpO2), SPG’s focus on microcirculation gives it an edge in capturing tissue-level oxygenation, including in capillaries and smaller vessels where oxygen exchange actually happens.
One key benefit of SPG is its robustness in low-perfusion states. PPG can struggle when blood flow is weak—think hypothermia, shock, or vascular occlusions—because it depends on a strong pulsatile signal from arteries. SPG, by contrast, doesn’t rely solely on pulsatile flow; it can detect subtle movements of red blood cells even in low-flow conditions, making it more reliable for monitoring tissue oxygenation in critically ill patients or during procedures where circulation is compromised.
Another advantage is SPG’s potential for higher spatial resolution. Since it’s often paired with imaging techniques, SPG can map oxygenation across a tissue area, revealing variations that PPG, which typically averages a single point, might miss. This could be a game-changer in scenarios like wound healing or burn assessment, where knowing oxygen distribution in tissue is more valuable than a single arterial snapshot.
SPG also tends to be less affected by motion artifacts in certain setups. PPG signals can get noisy if the sensor shifts or the patient moves, as it’s sensitive to changes in light absorption that aren’t related to blood volume. SPG, focusing on speckle contrast tied to blood cell motion, can sometimes filter out these distractions better, especially with advanced processing or imaging approaches. That said, this depends on the setup—contact-based SPG might still face motion challenges, but non-contact versions show promise here.
Sensitivity to deeper tissue layers is another plus for SPG. The coherent light it uses penetrates further than the LED light in PPG, which is often limited to superficial layers like the dermis. This deeper reach allows SPG to assess oxygenation in tissues beyond what PPG can reliably access, offering a more comprehensive picture of oxygen delivery and uptake.
Hemorai’s proprietary CSI technology, powered by Speckleplethysmography (SPG), accurately measures key physiological parameters, including:
- SpO2 (Arterial Oxygen Saturation): Provides insights into the percentage of oxygen-bound hemoglobin in arterial blood, reflecting the oxygen-carrying capacity critical for systemic oxygenation.
- TMR02 (Tissue Metabolic Rate of Oxygen): Quantifies the rate at which oxygen is consumed by tissues, offering a window into metabolic activity and tissue health at the microvascular level.
- Total Hematocrit: Measures the proportion of blood volume occupied by red blood cells, enabling assessment of blood concentration and its oxygen-delivery potential.
- Speckle Flow Index (SFI): Captures real-time blood flow dynamics in the microcirculation, detecting subtle fluctuations that may indicate hemorrhage, vascular shifts, or changes in perfusion.

Advanced Technology
The CSI system utilizes laser speckle imaging and spectroscopic analysis to measure vital parameters continuously and non-invasively. This technology is particularly effective for early detection and monitoring of hemorrhage, as it can detect subtle changes in tissue perfusion and oxygenation before traditional vital signs show significant changes.
A key advantage of our technology is its ability to work effectively across all skin types, as validated by extensive research showing that epidermal melanin content has minimal impact on measurement accuracy. This makes the CSI device a reliable tool for monitoring patients of all ethnicities in both clinical and emergency settings.

Early Detection Capabilities
Clinical studies have demonstrated the CSI device's ability to detect hemorrhage progression significantly earlier than conventional monitoring methods. The system's continuous monitoring capability enables healthcare providers to:
- Identify subtle changes in tissue perfusion
- Monitor treatment effectiveness in real-time
- Make timely, data-driven clinical decisions
- Improve patient outcomes through early intervention

Product Evolution
From laboratory concept to commercial product, our technology is evolving through three generations
Gen 1
Proof of Concept
Our journey began at UC Irvine with a benchtop prototype that validated our core technology. This initial version demonstrated the feasibility of using diffuse reflectance spectroscopy for hemorrhage detection.


Gen 2
We're HereWorking Prototype
Our second-generation model, developed in-house, features a compact, portable design with enhanced sensors and real-time processing capabilities. Currently, UMass Medical School is assisting in clinically validating this version to ensure its efficacy and reliability in real-world applications.
Currently running clinical validation studies while preparing for Gen 3 development starting January 2025.


Gen 3
Commercial Product
In partnership with WPI, our upcoming commercial version will feature a miniaturized, wearable design with wireless connectivity and extended battery life. Development begins January 2025.


Research Papers
Explore published research related to our technology